Shares of YIDU TECH (02158) have climbed more than 5%. At the time of writing, the stock is up 4.58%, trading at HK$5.48 with a turnover of HK$26.17 million.

The recent price movement follows significant company news. A key laboratory, the "Beijing Key Laboratory for the R&D and Transformation of Multimodal Intelligent Diagnosis and Treatment Systems," has been officially inaugurated. This initiative is led by Peking University First Hospital, with YIDU TECH as a co-builder. The lab's establishment marks a major step into advanced efforts to tackle the "black box" problem in AI healthcare, aiming to create a closed-loop system from data management to clinical decision-making.

The launch of this laboratory exemplifies YIDU TECH's deep integration into Beijing's strategic push for "AI + healthcare." The lab's first major research target is Cardiometabolic-Kidney Syndrome (CKM), with the goal of breaking down specialty barriers and shifting treatment towards intelligent, whole-process management focused on prevention and co-morbidity care.

In parallel, YIDU TECH has made substantial progress in practical applications. The company has collaborated with leading hospitals to develop over 280 specialized scenario AI agents. These are deeply embedded into real clinical environments, such as doctor workstations, and are already deployed in 133 renowned hospitals, including Peking Union Medical College Hospital, Peking University Cancer Hospital, and Tsinghua Chang Gung Hospital. These applications cover high-frequency, full-process needs like medical record generation, assisted diagnosis, and risk assessment.

Beyond specific projects, YIDU TECH is accelerating its broader ecosystem strategy. At the 2026 Global Digital Economy Conference, the company participated as a founding member in establishing the "Chaoyang District Medical and Health Data Element Ecosystem Alliance." This alliance aims to streamline the entire chain for medical and health data, from rights confirmation and circulation to value realization.